Got story updates? Submit your updates here. ›

Truist Financial has raised its price target on Dianthus Therapeutics (NASDAQ:DNTH) stock from $63 to $110, representing a potential upside of 68.71% from the stock’s current trading price. The brokerage firm maintained its “buy” rating on the biotech company’s shares.

Why it matters

This significant price target increase from a major financial institution signals strong confidence in Dianthus Therapeutics’ growth prospects and the potential value of its drug pipeline. It could drive increased investor interest and buying pressure for the stock.

The details

In a research note, Truist Financial cited Dianthus Therapeutics’…